|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00141921 |
|
Date of registration:
|
31/08/2005 |
|
Primary sponsor: |
|
|
Public title:
|
Pediatric Open-Label Extension Study
|
|
Scientific title:
|
An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis |
|
Date of first enrolment:
|
August 2005 |
|
Target sample size:
|
182 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00141921 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Canada
|
United States
| | | | | | |
|
Contacts
|
|
Name:
|
MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Amgen |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria: - Enrollment on previous Amgen study 20030211 Exclusion Criteria: -
Serious or clinically significant adverse event on Amgen study 20030211 related to
etanercept
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Pediatric Plaque Psoriasis
|
|
Intervention(s)
|
|
Drug: Etanercept
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|